SEC Form 4	
------------	--

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
--	--

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL						
OMB Number: 3235-0287						
Estimated average burden						

hours per response:	0.5

1. Name and Address of Reporting Person [*] Biomedical Sciences Investment Fund Pte Ltd.					2. Issuer Name and Ticker or Trading Symbol Vanda Pharmaceuticals Inc. [VNDA]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner Officer (give title Other (specify									
(Last)	(Fi	rst) (Middle)			Date of Earliest Transaction (Month/Day/Year) /15/2006								below			belov			
#09-01 4. If Am				f Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)								
(Street) CENTROS U0 138668													Form filed by One Reporting Person X Form filed by More than One Reporting Person							
(City)	(St	ate) (Zip)																	
		Tabl	e I - N	lon-Deriv	ative	Sec	uritie	s Ac	quire	d, D	isposed o			ially	Owne	ed				
1. Title of S	ecurity (Inst	r. 3)		2. Transacti Date (Month/Day		Execution Date, (ear) if any		3. Transaction Code (Instr. 8)		4. Securities Disposed Of	I. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and		Benefic		ies ially Following	Forr (D) c	wnership m: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A) or (D)	Price		Transac (Instr. 3	ction(s) and 4)			(
Common	Stock			11/15/20	006	6		S		25,711	D	\$15.1	1317 2,5		46,957	I (1)		See Footnote ⁽¹⁾		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	ivative Conversion Date Execution Date, 1 urity or Exercise (Month/Day/Year) if any 0			5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)		Derivative Security derivative Security (Instr. 5) Benefici Owned 3 Followir Reporte		9. Number derivative Securities Beneficiall Owned Following Reported Transactioi (Instr. 4)	e ss ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)				
					Code	v	(A)	(D)	Date Exerc	isable	Expiration Date	Title	Amount or Number of Shares							
		Reporting Person [*] nces Investme	<u>ent F</u> i	und Pte I	<u>.td.</u>															
(Last) (First) (Middle) 20 BIOPOLIS WAY																				
#09-01						_														
(Street))S	U0	1	38668		_														
(City)		(State)	(Z	lip)																
1. Name and Address of Reporting Person [*] Bio One Capital Pte Ltd.																				
(Last) (First) (Middle) 20 BIOPOLIS WAY #09-01																				
(Street) CENTROS U0 138668				-																
(City) (State) (Zip)				_																

1. Name and Address of Reporting Person*

EDB Investments Pte Ltd.

(Last)	(First)	(Middle)							
20 BIOPOLIS WAY									
#09-01									
(Street)									
CENTROS	U0	138668							
(City)	(State)	(Zip)							

Explanation of Responses:

1. Securities owned directly by BioMedical Sciences Investment Fund Pte Ltd. These securities may be deemed to be beneficially owned by Bio*One Capital Pte Ltd ("Bio*One"), the fund manager of BioMedical Sciences Investment Fund Pte Ltd ("BSIF") and EDB Investments Pte Ltd ("EDBI"), the parent company of BSIF and Bio*One. Each of Bio*One and EDBI disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein, and this report shall not be deemed an admission that Bio*One or EDBI is the beneficial owner of the securities for any purpose, except to the extent of its pecuniary interest therein.

Remarks:

<u>/s/ Sim Sze Kuan</u>	<u>11/15/2006</u>
<u>Sim Sze Kuan, Attorney in</u> <u>Fact for Bio*One Capital Pte</u> <u>Ltd</u>	<u>11/15/2006</u>
Sim Sze Kuan, Attorney in Fact for EDB Investments Pte Ltd	<u>11/15/2006</u>
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.